Cost-effectiveness of first-line hormone-therapies in chemonaïve castration-resistant prostate cancer Integrating the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) with the costs of drugs
Attendere...
Giugno 2017, Vol. 108, N. 6
Recenti Prog Med 2017;108(6):294-295
doi 10.1701/2715.27717
Giuliani J, Bonetti A. Cost-effectiveness of first-line hormone-therapies in chemonaïve castration-resistant prostate cancer Integrating the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) with the costs of drugs. Recenti Prog Med 2017;108(6):294-295. doi 10.1701/2715.27717
Scarica la citazione:
PER VISUALIZZARE IL TESTO COMPLETO EFFETTUARE L'ACCESSO
